Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Equinox Gold und Orla Mining schließen sich zusammen und bilden Nordamerikas neuen führenden... (IRW Press) +++ ORLA MINING Aktie -3,20%

Foren & Soziale Netzwerke zur ABEONA THERAPEUTICS Aktie

 >Aktienkurs 
5.2 EUR    +7.4%    (TradegateBSX)
Ask: 5.098 EUR / 300 Stück
Bid: 4.857 EUR / 350 Stück
Tagesumsatz: 5960 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -1,8%
1 Monat: +19,2%
3 Monate: +17,1%
6 Monate: +11,2%
1 Jahr: -5,0%
laufendes Jahr: +7,3%
>ABEONA THERAPEUTICS Aktie
Name:  ABEONA THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00289Y2063 / A3DMHM
Symbol/ Ticker:  PCJ (Frankfurt) / ABEO (NASDAQ)
Kürzel:  FRA:PCJ, ETR:PCJ, PCJ:GR, NASDAQ:ABEO
Index:  -
Webseite:  https://www.abeonatherape..
Profil:  Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious, life-threatening rare diseases. Its flagship product, ZEVASKYN (prademagene zamikeracel), is the first and only autologous cell-b..
>Volltext..
Marktkapitalisierung:  284.75 Mio. EUR
Unternehmenswert:  142.53 Mio. EUR
Umsatz:  4.96 Mio. EUR
EBITDA:  -73.15 Mio. EUR
Nettogewinn:  60.63 Mio. EUR
Gewinn je Aktie:  1.16 EUR
Schulden:  21.27 Mio. EUR
Liquide Mittel:  66.81 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  6.47
Umsatzwachstum:  -
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 33.073 USD.
Suchwörter:  ABEONA THERAPEUTICS, ABEONA THERAPEUTIC
Letzte Datenerhebung:  13.05.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 57.05 Mio. St.
Frei handelbar: 84.7%
Rückkaufquote: -7.8%
Mitarbeiter: 226
Umsatz/Mitarb.: 0.02 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 232.73%
Bewertung:
KGV: 6.04
KGV lG: -
KUV: 51.95
KBV: 2.08
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -16.13%
Gewinnmarge: 1223.08%
Operative Marge: -1536.91%
Managementeffizenz:
Gesamtkaprendite: 43.13%
Eigenkaprendite: 70.05%
>Peer Group
 
10.03.26 - 15:03
 HC_Wainwright: buy Abeona Therapeutics Inc. (Sharewise)
 
Kursziel: 17.204 €
15.08.25 - 17:03
 Oppenheimer_Holdings: buy Abeona Therapeutics Inc. (Sharewise)
 
Kursziel: 17.158 €
14.07.25 - 15:03
 HC_Wainwright: buy Abeona Therapeutics Inc. (Sharewise)
 
Kursziel: 17.112 €
02.06.25 - 16:18
 Oppenheimer_Holdings: buy Abeona Therapeutics Inc. (Sharewise)
 
Kursziel: 16.7105 €
16.05.25 - 20:33
 Stifel_Nicolaus: buy Abeona Therapeutics Inc. (Sharewise)
 
Kursziel: 17.854 €
30.04.25 - 16:30
 ABEO is undervalued; Market has NOT priced in FDA approval news. (TradingView)
 
Looks like a good monthly or longer play for the following reasons: 1. Beginning to see elevated RVOL (although it is Pre) in the hundreds. 2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarters irrelevant (as they can now fully market and distribute the treatment, which will fix prior low rev issues, because its an R&D company), b) they were only losing about 40mil a quarter before which again, is actually relatively low compared to other pharma-dev companies (many have like 20mil + burn per quarter). 3. stock is trading at a consolidation region below the gap, for the last few years. (avg range between 3-5$, with some spikes between) 4. managed to stay in the NASDAQ due to a 25/1 reverse split, which many times just continues to crush the company stock, but this one has held steadfast in this lower region for the last three years. 5. Post RS, the price has trended slowly up, with higher lows, and
30.04.25 - 16:21
 ABEO is undervalued based on recent FDA approval news. (TradingView)
 
Looks like a good monthly or longer play for the following reasons: 1. Beginning to see elevated RVOL (although it is Pre) in the hundreds. 2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarters irrelevant (as they can now fully market and distribute the treatment, which will fix prior low rev issues, because its an R&D company), b) they were only losing about 40mil a quarter before which again, is actually relatively low compared to other pharma-dev companies (many have like 20mil + burn per quarter). 3. stock is trading at a consolidation region below the gap, for the last few years. (avg range between 3-5$, with some spikes between) 4. managed to stay in the NASDAQ due to a 25/1 reverse split, which many times just continues to crush the company stock, but this one has held steadfast in this lower region for the last three years. 5. Post RS, the price has trended slowly up, with higher lows, and
27.04.25 - 20:57
 BiotechBee: buy Abeona Therapeutics Inc. (Sharewise)
 
Kursziel: 6.0 €
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Denn wenn es Kunst ist, ist sie nicht für alle, und wenn sie für alle ist, ist sie keine Kunst. - Arnold Schönberg
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!